Senior Life Sciences jobs in Switzerland: where VP and Director roles actually appear
The Swiss Life Sciences cluster — from the Basel pharma corridor to the Zürich biotech hub — is one of the densest concentrations of senior roles in the world. Here is where they surface, and where they don't.
Switzerland employs more Life Sciences executives per capita than almost any other country. Novartis, Roche, Lonza, Alcon, Straumann, Galderma, Medacta, and hundreds of smaller biotech and MedTech companies cluster within two hours of each other in the arc from Geneva to Basel to Zürich. Senior roles here are some of the most coveted in the industry.
The public board problem
The Swiss Life Sciences labour market shares the same fundamental asymmetry as the global one, amplified. Most VP and C-suite mandates are filled through retained search firms — Egon Zehnder (Zürich), Russell Reynolds, Spencer Stuart — or through internal succession planning and direct referral. What appears publicly is the residue.
That said, a meaningful volume of Director and Senior Director-level roles is posted publicly, particularly at CRO/CDMO companies (Lonza, Bachem, Polpharma Biologics) and mid-size MedTech firms. The public boards worth monitoring in Switzerland include Greenhouse-posted roles from Swiss ATS users, Adzuna Switzerland, Jobup.ch, and company career pages directly.
The seniority threshold matters
Below Director level, public job boards are reasonably representative. Above VP level, they are decorative.
For a VP or C-suite professional, the implication is clear: passive monitoring of public boards is not a viable strategy. The roles worth having are not there, or they are there long after the shortlist has been formed. The only viable alternative is a continuous, automated scout — something running while you are in your current role, checking daily, catching the publicly-posted roles that do exist before they are filled.
What the Basel–Zürich corridor actually pays
For context: VP-level roles in the Basel pharma corridor (Novartis, Roche, Lonza) typically carry base salaries of CHF 250k–340k plus bonus. The Zürich biotech cluster (including UK-listed and US-listed companies with Swiss operations) often includes equity alongside a CHF 220k–290k base. MedTech (Alcon, Straumann, Medacta) sits slightly lower on base, typically CHF 200k–270k at VP level, with strong long-term incentive plans.
These figures are drawn from roles that disclosed compensation in our matching corpus. Roughly 40% of Swiss senior roles disclose salary — higher than the EU average, lower than the UK.